Findings

What do systematic reviews say?

6 questions · 6 findings · 2 reviews · Gut

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 50%Low 3 · 50%Moderate 0 · 0%High 0 · 0%

Infliximab vs biosimilar

Serious adverse events (at 52 weeks) · patients with Crohn's disease (with mixed/low disease activity at baseline)

Infliximab showed no clear difference in serious adverse events (at 52 weeks) compared with biosimilar (low certainty).

1 finding from 1 review

Infliximab for maintenance of medically‐induced remission in Crohn's disease 2024 · Cochrane Headline outcomes only
RR 0.99 [0.39, 2.5]
1 study · 155 participants
Low

Infliximab vs adalimumab

Serious adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline)

It is very uncertain whether infliximab changes serious adverse events (at 56 weeks) compared with adalimumab (very low certainty).

1 finding from 1 review

Infliximab for maintenance of medically‐induced remission in Crohn's disease 2024 · Cochrane Headline outcomes only
RR 0.09 [0.01, 1.54]
1 study · 73 participants
Very low

Infliximab vs placebo

Serious adverse events (at 54 weeks) · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)

It is very uncertain whether infliximab changes serious adverse events (at 54 weeks) compared with placebo (very low certainty).

1 finding from 1 review

Infliximab for maintenance of medically‐induced remission in Crohn's disease 2024 · Cochrane Headline outcomes only
RR 0.6 [0.36, 1]
1 study · 282 participants
Very low

Vedolizumab vs placebo

Serious adverse events (6–10 weeks) · people with Crohn's disease

Vedolizumab showed no clear difference in serious adverse events (6–10 weeks) compared with placebo (low certainty).

1 finding from 1 review

Vedolizumab for induction and maintenance of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
RR 0.91 [0.62, 1.33]
4 studies · 1126 participants
Low

Vedolizumab vs placebo

Serious adverse events (52–60 weeks) · people with Crohn's disease

Vedolizumab showed no clear difference in serious adverse events (52–60 weeks) compared with placebo (low certainty).

1 finding from 1 review

Vedolizumab for induction and maintenance of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
RR 0.98 [0.68, 1.39]
3 studies · 894 participants
Low

Infliximab combined with purine analogues vs purine analogues

Serious adverse events (at 48 weeks to 2 years) · Participants with Crohn's disease in remission

It is very uncertain whether infliximab combined with purine analogues changes serious adverse events (at 48 weeks to 2 years) compared with purine analogues (very low certainty).

1 finding from 1 review

Infliximab for maintenance of medically‐induced remission in Crohn's disease 2024 · Cochrane Headline outcomes only
RR 1.19 [0.54, 2.64]
2 studies · 257 participants
Very low